Skip to content
Chromosomal microarray better informs brain tumor diagnosis: Robert Jenkins, M.D., Ph.D. episode artwork

Feb 21, 2023 23 min

Chromosomal microarray better informs brain tumor diagnosis: Robert Jenkins, M.D., Ph.D.

from Answers from the Lab Hosted by Mayo Clinic Laboratories

(00:31) Could you provide a little bit about yourself and your background? (02:04) Could you provide an overview of the chromosomal microarray assay? (05:49) Why should the chromosomal microarray assay be used over other available assays, such as FISH? (08:56) Does the chromosomal microarray provide good benefits in terms of gain of 7 and loss of 10, and EGFR amplification? (12:03) What's the value of utilizing the test alongside a neuro-specific NGS panel, such as Mayo Clinic Laboratories' NONCP panel? (17:20) How are the results used in patient care? (19:41) Is there anything else you feel it's important to highlight?

Episode details come from the podcast's RSS feed.

Embed this episode

Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray assay outperforms other tests for brain tumor analysis. The microarray aligns with the World Health Organization's latest classification of central nervous system tumors.

Ready to play

Chromosomal microarray better informs brain tumor diagnosis: Robert Jenkins, M.D., Ph.D.

0:00 23:57

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Answers from the Lab?

This episode is 23 minutes long.

When was this Answers from the Lab episode published?

This episode was published on February 21, 2023.

Can I download this Answers from the Lab episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.